A proposed EU-US trade agreement could impose a 15% tariff on branded medicines, potentially adding up to $19 billion in costs for the pharmaceutical industry and prompting major strategy shifts in global drug supply chains.
A proposed trade deal between the European Union and the United States could bring significant changes to how pharmaceuticals are priced, shipped, and sourced across global markets. The deal, which is still under negotiation, includes a 15% tariff on branded drugs, making it the first time pharmaceuticals would face such duties in the transatlantic trade corridor. While some generic drugs will remain tariff-free, the wider impact on branded medicine exports from the EU to the US – currently its largest pharmaceutical market – could be substantial.
According to The Economic Times, medicines are the highest-value European export to the United States, and the EU currently supplies close to 60% of all pharmaceutical imports to the country. The inclusion of branded medicines under the proposed tariff framework could lead to industry costs rising by as much as $19 billion, according to analysts. While some expect pharmaceutical firms to absorb a part of these costs through operational adjustments, others believe these tariffs could eventually lead to higher consumer prices unless alternative mitigation strategies are applied.
Wall Street analysts remain divided on how the US will proceed. Some, including UBS analyst Matthew Weston, believe that the trade deal may shield EU drug exports from a separate national security investigation the US is currently conducting on the pharmaceutical sector. That investigation has raised concerns in the past, with statements from President Donald Trump suggesting that pharma tariffs could reach up to 200%, though such figures have not been formalized.
Diederik Stadig of ING believes that while no additional tariffs are expected beyond the 15%, the absence of a signed agreement leaves room for uncertainty. He estimates that the added cost to the pharmaceutical industry could reach $13 billion if no mitigating steps are taken, such as logistical reconfigurations, local production shifts, or supply chain stockpiling.
Some pharmaceutical companies are already responding. Sanofi recently announced the sale of its New Jersey manufacturing facility to Thermo Fisher Scientific, which will continue producing the company’s therapies on site, likely a pre-emptive move to ensure uninterrupted US supply. Similarly, Roche has begun increasing inventory in the US, preparing for possible disruptions if tariffs are introduced. Sandoz, one of the world’s largest producers of generic drugs, is expected to remain mostly unaffected this year, though details on which generics will be exempt from the tariffs are not yet public.
Bernstein analyst Courtney Breen estimates that the impact could go as high as $19 billion, but notes that companies with robust contingency planning may be able to soften the blow. Strategies such as entering new contract research partnerships or building inventory buffers could help manage the financial strain.
While the pharmaceutical industry awaits clarity on the final terms, the possibility of long-term trade barriers is already pushing manufacturers to re-evaluate supply chains and production footprints. If finalized, the deal could reshape not only cost structures, but also where and how medicines are made for global markets – including India, which is likely to monitor the developments closely as both a generic supplier and a growing biopharma hub.